Leukocyte Adhesion Deficiency Type 1
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Leukocyte Adhesion Deficiency Type 1

What is the definition of Leukocyte Adhesion Deficiency Type 1?

Leukocyte adhesion deficiency type 1 is a disorder that causes the immune system to malfunction, resulting in a form of immunodeficiency. Immunodeficiencies are conditions in which the immune system is not able to protect the body effectively from foreign invaders such as viruses, bacteria, and fungi. Starting from birth, people with leukocyte adhesion deficiency type 1 develop serious bacterial and fungal infections.

What are the causes of Leukocyte Adhesion Deficiency Type 1?

Mutations in the ITGB2 gene cause leukocyte adhesion deficiency type 1. This gene provides instructions for making one part (the β2 subunit) of at least four different proteins known as β2 integrins. Integrins that contain the β2 subunit are found embedded in the membrane that surrounds white blood cells (leukocytes). These integrins help leukocytes gather at sites of infection or injury, where they contribute to the immune response. β2 integrins recognize signs of inflammation and attach (bind) to proteins called ligands on the lining of blood vessels. This binding leads to linkage (adhesion) of the leukocyte to the blood vessel wall. Signaling through the β2 integrins triggers the transport of the attached leukocyte across the blood vessel wall to the site of infection or injury.

How prevalent is Leukocyte Adhesion Deficiency Type 1?

Leukocyte adhesion deficiency type 1 is estimated to occur in 1 per million people worldwide. At least 300 cases of this condition have been reported in the scientific literature.

Is Leukocyte Adhesion Deficiency Type 1 an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Leukocyte Adhesion Deficiency Type 1 Local Doctors?
Elite in Leukocyte Adhesion Deficiency Type 1
Elite in Leukocyte Adhesion Deficiency Type 1
Madrid, MD, ES 

Elena Almarza practices practicing medicine in Madrid, Spain. Ms. Almarza is rated as an Elite expert by MediFind in the treatment of Leukocyte Adhesion Deficiency Type 1. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Leukocyte Adhesion Deficiency Type 1, Osteopetrosis, Congenital Aplastic Anemia, and Fanconi Anemia.

Elite in Leukocyte Adhesion Deficiency Type 1
Elite in Leukocyte Adhesion Deficiency Type 1
Madrid, MD, ES 

Juan Bueren practices practicing medicine in Madrid, Spain. Mr. Bueren is rated as an Elite expert by MediFind in the treatment of Leukocyte Adhesion Deficiency Type 1. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Fanconi Anemia, Congenital Aplastic Anemia, Aplastic Anemia, Leukocyte Adhesion Deficiency Type 1, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Leukocyte Adhesion Deficiency Type 1
Hematology | Oncology
Elite in Leukocyte Adhesion Deficiency Type 1
Hematology | Oncology

Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
Languages Spoken:
English

Jonathan Schwartz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Schwartz is rated as an Elite provider by MediFind in the treatment of Leukocyte Adhesion Deficiency Type 1. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Fanconi Anemia, Congenital Aplastic Anemia, Danon Disease, Leukocyte Adhesion Deficiency Type 1, and Splenectomy.

What are the latest Leukocyte Adhesion Deficiency Type 1 Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: April 01, 2014
Published By: National Institutes of Health